#### Improving reporting standards for polygenic scores in risk 1 prediction studies 2

3

4 Hannah Wand<sup>#1,2</sup>, Samuel A. Lambert<sup>#3-7</sup>, Cecelia Tamburro<sup>8</sup>, Michael A. Iacocca<sup>1</sup>, Jack W. O'Sullivan<sup>1,2</sup>, Catherine Sillari<sup>8</sup>, Iftikhar J. Kullo<sup>9</sup>, Robb Rowley<sup>8</sup>, Deanna Brockman<sup>10</sup>, Eric Venner<sup>11</sup>, Mark I. 5 McCarthy<sup>12,13</sup>, Antonis C. Antoniou<sup>14</sup>, Douglas F. Easton<sup>14</sup>, Robert A. Hegele<sup>15</sup>, Amit V. Khera<sup>10</sup>, Nilanjan 6 Chatterjee<sup>16,17</sup>, Charles Kooperberg<sup>18</sup>, Karen Edwards<sup>14</sup>, Katherine Vlessis<sup>20</sup>, Kim Kinnear<sup>20</sup>, John N. 7 Danesh<sup>5,6</sup>, Helen Parkinson<sup>6,7</sup>, Erin M. Ramos<sup>8</sup>, Megan C. Roberts<sup>15</sup>, Kelly E. Ormond<sup>20,22</sup>, Muin J. Khoury<sup>23</sup>, 8 A. Cecile J.W. Janssens<sup>24</sup>, Katrina A.B. Goddard<sup>25,26</sup>, Peter Kraft<sup>27</sup>, Jaqueline A. L. MacArthur<sup>7</sup>, Michael 9 Inouye<sup>\$3-6,28,29</sup>, Genevieve Wojcik<sup>\$30</sup> 10

11

12 #Shared first authorship

- 13 \$Shared senior authorship
- 14 15

17

18

19

20

21

22

23

27

28

35

36

37

38

39

40

41

42

45

46

- 1. Stanford University School of Medicine, Stanford, CA, USA
- 16 2. Stanford Center for Inherited Cardiovascular Disease, Stanford, CA, USA
  - 3. Cambridge Baker Systems Genomic Initiative, University of Cambridge, Cambridge, UK
  - 4. Cambridge Baker Systems Genomic Initiative, Baker Heart and Diabetes Institute, Melbourne, AUS
    - 5. BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
      - 6. Health Data Research UK-Cambridge, Wellcome Genome Campus, Hinxton, UK
    - 7. European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, UK
    - 8. National Human Genome Research Institute, Bethesda, MD, USA
- 24 25 9. Mayo Clinic, Rochester, MN, USA 26
  - 10. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
  - 11. Baylor College of Medicine, Houston, TX, USA
  - 12. Department of Human Genetics, Genentech, South San Francisco, CA, USA
- 29 13. Wellcome Centre for Human Genetics, Oxford, UK
- 30 14. University of Cambridge, Cambridge, United Kingdom
- 31 15. Western University, London, ON, Canada
- 32 16. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 33 17. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA 34
  - 18. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  - 19. Department of Epidemiology, University of California, Irvine, CA, USA
  - 20. Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
  - 21. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
    - 22. Stanford Center for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA, USA
  - 23. Centers for Disease Control and Prevention, Atlanta, GA, USA
  - 24. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
  - Department of Translational and Applied Genomics, Kaiser Permanente Northwest, Portland, OR, USA
- 43 26. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA 44
  - 27. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  - 28. National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
  - 29. The Alan Turing Institute, London, UK
    - 30. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 48 49
- 50 \*Corresponding author: Dr. Genevieve L. Wojcik, gwojcik1@jhu.edu

## 51 Summary

52 In recent years, polygenic risk scores (PRS) have become an increasingly studied tool to capture the 53 genome-wide liability underlying many human traits and diseases, hoping to better inform an individual's 54 genetic risk. However, a lack of adherence to previous reporting standards has hindered the translation of 55 this important tool into clinical and public health practice with the heterogeneous underreporting of details 56 necessary for benchmarking and reproducibility. To address this gap, the ClinGen Complex Disease 57 Working Group and Polygenic Score (PGS) Catalog have collaborated to develop the 33-item Polygenic 58 Risk Score Reporting Statement (PRS-RS). This framework provides the minimal information expected of 59 authors to promote the internal validity, transparency, and reproducibility of PRS by requiring authors to 60 detail the study population, statistical methods, and clinical utility of a published score. The widespread 61 adoption of this framework will encourage rigorous methodological consideration and facilitate 62 benchmarking to ensure high quality scores are translated into the clinic.

# 64 Introduction

65 The predisposition to common diseases and traits arises from a complex interaction between genetic and 66 nongenetic factors. During the past decade, international collaborations involving cataloged human genetic 67 variation, and large cohorts of well-phenotyped individuals with matched genotype information have 68 enabled the discovery of disease-associated genetic variants.<sup>1-4</sup> In particular, genome-wide association 69 studies (GWAS) have emerged as a powerful approach to identify disease- or trait-associated genetic 70 variants, typically yielding summary statistics describing the magnitude (effect size) and statistical 71 significance of association between an allele and the trait of interest.<sup>4,5</sup> GWAS have been applied to a wide 72 range of complex human traits and diseases, including height, blood pressure, cardiovascular disease, 73 cancer, obesity, and Alzheimer's disease.

74

75 The associations identified via GWAS can quantify genetic predisposition to a heritable trait, which can be 76 used to conduct disease risk stratification or predict prognostic outcomes and response to therapy.<sup>6,7</sup> 77 Typically, information across many variants is used to form a weighted sum of allele counts across variants, 78 where the weights reflect the magnitude of association between variant alleles and the trait or disease. 79 These weighted sums can include up to millions of variants, and are frequently referred to as **polygenic** 80 risk score(s) (PRS), or genetic or genomic risk score(s) (GRS), if they refer to disease risk; or, more 81 generally, polygenic score(s) (PGS) when referring to any phenotype (see Box 1 for further discussion of 82 nomenclature). While there is active development of algorithms to decide how many and which variants to 83 include and how much to weigh them so as to maximize the proportion variance explained or the disease 84 discrimination, there is an emerging consensus that the inclusion of variants beyond those meeting stringent 85 GWAS significance levels can boost predictive performance.<sup>8,9</sup>

### Box 1. Definitions of relevant genetic risk prediction terms

**Polygenic Score(s) (PGS):** a single value that estimates the genetic contribution to inter-individual variation in a trait. Typically calculated by summing the number of trait-associated alleles in an individual, weighted by per-allele effect sizes from a discovery GWAS. Sometimes referred to as a genetic score. **Polygenic Risk Score(s) (PRS):** a PGS which is used to estimate risk of disease or other clinically relevant outcomes (binary or discrete). Sometimes referred to as a genetic or genomic risk score (GRS). See categories of PRS below.

**Integrated Risk Model:** a risk model combining PGS/PRS with other established risk factors, such as demographics (often age and sex), anthropometrics, biomarkers, and clinical measurements to estimate a specific disease risk.

### Categories of use for PRS and/or integrated risk models

The addition of PRS to existing risk models has several potential applications, summarized below. In each, the aim of PRS integration is to improve individual or subgroup classification to the extent that there is clinical benefit.

**Disease Risk Prediction** – used to estimate an individual's risk of developing a disease, based on the presence of certain genetic and/or clinical variables.

**Disease Diagnosis** – used to classify whether an individual has a disease, or a disease subtype, linked to a certain etiology based on the presence of certain genetic and/or clinical variables.<sup>8,10</sup>

**Disease Prognosis** – used to estimate the risk of further adverse outcome(s) *subsequent to* diagnosis of disease.<sup>11</sup>

Therapeutic – used to predict a patient or subgroup's response to a particular treatment.<sup>12</sup>

87

88 Frameworks have been developed to establish standards around the transparent, standardized, accurate,

89 complete and meaningful reporting of scientific studies. Those relevant for development and validation of

<sup>90</sup> risk prediction models include PICOT<sup>13</sup>, TRIPOD<sup>14</sup>, STROBE<sup>15</sup>, STREGA<sup>16</sup>, and, notably, the Genetic Risk

91 Prediction Studies (GRIPS) Statement<sup>17</sup> which specifically address reporting of *genetic* risk prediction

92 studies. However, no framework adequately addresses the emerging use of PRS in clinical care and

- 93 disease prevention.
- 94

95 It is time to update the GRIPS statement as PRS have become ubiquitous in genetic research while 96 reporting remains heterogeneous, particularly in terms of transparency and enabling reproducibility. The 97 methods utilised for PRS construction and risk-model development have become more diverse and 98 sophisticated.<sup>18–20</sup> Biobanks and large-scale consortia have become dominant, yet frequently have limited 99 access to individual-level data. Standards for reporting genetic ancestry information have been developed<sup>1</sup>, 100 and there is a push towards open data sharing as outlined in the FAIR (Findable, Accessible, Interoperable 101 and Reusable) Data Principles.<sup>3,21</sup> Finally, the rapid rise of direct-to-consumer assays and companies

- (including 23andMe, Color, MyHeritage, etc.) providing PGS/PRS results to customers has vastly increased the scope and complexity of genetic risk information. The readiness of PRS for implementation varies among phenotypes, with only a few diseases like breast cancer <sup>22–24</sup> and coronary heart disease (CHD) having mature PRS with potential clinical utility (see Box 2 for additional discussion of CHD). These concomitant advances have resulted in healthcare systems developing new infrastructures to deliver genetic risk information, and the field now needs to develop standards for clinical applications of PRS.
- 108

### Box 2: Current CHD PRS and their potential uses

While many PRS have been developed to predict CHD, they vary greatly in the computational methods used to develop them, the number of variants included (50–6,000,000), and the GWAS and cohorts used for PRS training. For example, the latest and currently most predictive CHD PRS use GWAS summary statistics from the CardiogramPlusC4D study <sup>25</sup>, and mainly differ by the computational methods used to select the included variants (including LDpred<sup>26,27</sup>, lassosum<sup>28</sup>, and meta-scoring approaches<sup>29</sup>), and how they are combined into risk models. These PRS, however, may provide useful information for predicting risk of CHD being largely orthogonal to conventional risk factors (age, sex, blood pressure, cholesterol, BMI, smoking) as well as family history. Clinical applications may include:

- Improved risk prediction for future adverse cardiovascular events when added to traditional risk models (including Framingham Risk Score<sup>30</sup>, Pooled Cohort Equations<sup>28,29</sup>, QRISK<sup>28</sup>).
- Reclassification of risk categories often leading to recommendations related to risk-reducing treatments like statins.<sup>30–32</sup>

While the data strongly suggest CHD PRS, by refining risk estimates, may improve patient outcomes, clinical utility through randomized clinical trials has yet to be conclusively established. We anticipate this is the future direction of PRS studies, and a number of clinical trials are underway.<sup>33</sup>

109

110 At present, there are no uniformly agreed best practices for developing PRS nor any regulation or standards

111 for reporting or assessing their clinical readiness. These deficiencies are barriers to PRS being interpreted,

112 compared, and reproduced, and must be addressed to enable the application of PRS to improve clinical

- 113 practice and public health. Here, the Clinical Genome Resource (ClinGen) Complex Disease Working
- 114 Group and the Polygenic Score (PGS) Catalog jointly present reporting standards that address current PRS
- research and highlight a complementary centralized repository for PRS with the ClinGen-PGS Catalog joint
- 116 Polygenic Risk Score Reporting Standards (PRS-RS). We outline a foundation for transparent,
- 117 standardized, accurate, and clinically meaningful reporting on PRS development and validation in the

118 literature to overcome these barriers.



119 120

121 Figure 1: Prototype of PRS development and validation process. Figure 1 displays prototypical steps 122 for PRS construction, development, validation, and performance, with select aspects of the ClinGen PRS 123 reporting guideline highlighted throughout. In PRS development, variants associated with a phenotype of 124 interest, typically identified from a GWAS, are combined as a weighted sum of allele counts across variants. 125 Methods for optimizing variant selection for a PRS (PRS Construction) are not shown. The PRS is tested 126 in a risk model predicting the phenotype of interest and may be combined with other non-clinical variables. 127 Collectively, all variables included in the risk model are referred to as the risk model parameters. After fitting 128 procedures to select the best risk model, this model is validated in an independent sample. The 129 performance of a model is demonstrated though risk score distribution, discrimination, predictive ability, 130 and calibration. Though not displayed in the figure, these same results should also be reported for the 131 training sample for comparison to the validation sample. In both training and validation cohorts, the 132 phenotype of interest criteria, demographics, genotyping, and non-genetic variables should be reported (Table 1). 133

# 134 Results

#### 135 Updated PRS Reporting Guidelines

This guideline aims to specify the minimal criteria needed to accurately interpret a PRS and reproduce results throughout the PRS development process, briefly illustrated in Figure 1. It applies to the development and validation studies for PRS that aim to predict disease, prognosis and response to therapies. **Table 1** presents the full PRS-RS.

140

141 **Reporting on risk score background:** As the PRS-RS are focused on future utility and implementation, 142 authors must outline the study and target population and appropriate outcomes to understand what risk is 143 measured. Authors should use the appropriate data needed to address the intended clinical use, with 144 adequate documentation of dataset characteristics to inform understanding of the nuance in measured risk. 145 For example, when developing a risk score, there can be disparities between the risk-score predicted 146 clinical end-outcome (e.g., cardiovascular risk) and the measured phenotype of interest (e.g., LDL 147 cholesterol) used in the analysis. If a surrogate outcome is used, this should be clearly stated with an 148 explanation including the limitations of the study design or study recruitment method, in which the clinical 149 end outcome was not measured.

150

151 Reporting on populations: The "who, where, and when" of risk depend on the study population used to 152 derive the risk model. Therefore, authors need to define and characterize the demographics of their study 153 population, especially the age, sex, and ancestry composition. There are often inconsistent definitions and 154 levels of detail associated with ancestry, and the transferability of genetic findings between different 155 racial/ethnic groups can be limited. <sup>1,8,34</sup> It is essential for authors to define participants based on their self-156 identified ancestry, with a standardized framework developed by the NHGRI-EBI GWAS Catalog to enable 157 comparability between studies.<sup>1</sup> While these three demographic variables are the most universally relevant, 158 authors should provide sufficient level of detail for all relevant factors for the outcome of interest, especially 159 if they are included in the final risk model under risk model parameter specifications.

161 Reporting on Methods: There are currently several methods that are commonly used to select variants 162 and fine-tune weights. 7,18-20,35 As the performance and limitations of the risk score are dependent on these 163 methods, authors must provide complete details including the source of genetic information (risk model 164 genetic data acquisition) and inclusion/exclusion criteria (risk model parameter specifications). Once these 165 parameters are defined, authors should describe the methods used to transform the raw data, often derived 166 from GWAS summary statistics, to a sum of variants for their polygenic risk score estimation. Often authors 167 will iterate through numerous models to find the optimal fit. Therefore, in addition to the estimation methods, 168 it is important to detail the statistical model fitting procedure, including the measures used for the final model 169 selection.

170

171 Reporting on Risk Estimation: Translating the continuous PRS distribution to a risk estimate, whether 172 absolute or relative, is highly dependent on assumptions about and limitations with the specific data set 173 utilised. When describing the risk model type, authors should detail the time scale employed for prediction 174 or the study period/follow-up time for a relative hazard model. Additionally, if relative risk is estimated, the reference group should be well described. These details should be described for the training set, as well as 175 176 validation and sub-group analyses. The risk score calibration and discrimination should be described for all 177 analyses, although their estimation and interpretation are most relevant for validation, preferably with an 178 external validation set. Any differences in variable definitions between the training and validation sets 179 should be described.

180

**Reporting on Model Parameters:** Reporting actual estimates, not only the methods behind decisionmaking, enables readers to gauge the relative value of an increase in performance against other trade-offs. Making the underlying PRS (variant alleles and derived weights) publicly available and submitting them to the PGS Catalog allows others to reuse existing models (with known validity) and enables direct benchmarking between different PRS for the same trait. The current mathematical form of most PRS—a linear combination of allele counts—facilitates model description and reproducibility. Future genomic risk models may have more complicated forms, e.g. allowing for non-linear epistatic and gene-environment

interactions. It will be important to describe these models in sufficient detail to allow their implementation
by other researchers and clinical groups; this might entail sharing open-source code.

190

**Reporting on Interpretation**: By explicitly describing the *risk model's interpretation* and outlining potential *limitations* to the *generalizability* of their model, authors will empower readers and the wider community to better understand the risk score and its relative merits. Authors should justify the clinical relevance and *riskscore intended purpose*, such as how the performance of their PRS compares to other commonly used risk metrics, either from previously published PRS or conventional risk calculators, such as the pooled cohort equations for estimating atherosclerotic cardiovascular disease risk.<sup>36</sup> This is important — what indicates a "good" prediction can differ between outcomes and *intended purposes*.

198

Lastly, we would like to reiterate the need for both methodological and data transparency. Deposition in a resource such as the PGS Catalog provides an invaluable resource for widespread adoption and improvement of a published PRS. *Supplemental Table 1* provides additional reporting considerations on top of the minimal reporting framework in **Table 1**. Authors intending downstream clinical implementation should aim for the level of transparent and comprehensive reporting covered in both **Table 1** and *Supplemental Table 1*, especially those related to discussing the interpretation, limitations, and generalizability of results.

206 Compatibility with the PGS Catalog submission template

207 The PGS Catalog (www.PGSCatalog.org; Lambert et al., 2019) provides access to PGS scores and related 208 metadata to support the FAIR principles of data stewardship <sup>21</sup>, enabling subsequent applications and 209 assessments of PGS performance and best practices. The goals of the PGS Catalog align with ClinGen 210 with slight differences in how the data is represented in the Catalog (link). Overall, there is a good 211 agreement between the PRS-RS and PGS Catalog representation schema (field by field mapping outlined 212 in Supplemental Table 2A), particularly with respect to how study participants are described. Reporting 213 items in the PRS-RS that are not present in the PGS Catalog (Supplemental Table 2B) include descriptions, 214 goals, limitations and intended uses of PRS predictions and implementation that are not essential to the

- 215 Catalog's goal of indexing available published PGS with the metadata essential for interpretation and
- 216 reproducibility. PRS described using the PRS-RS items contain sufficient detail for their addition to the PGS
- 217 Catalog, as such we recommend that authors describe scores using the PRS-RS and submit them to the
- 218 PGS Catalog upon publication.
- 219
- 220

#### Box 3. Many papers lack sufficient detail for interpretation

We carried out a iterature review (representative across a variety of diseases, risk score categories, and populations) to revise the PRS-RS (N=30). It revealed multiple reporting items with insufficient and/or missing details as well as variable details provided on methods, results, and discussion (*Figure 2*). Papers had insufficient detail for items related to study design and variables, particularly phenotype of interest (inclusion/exclusion criteria and control definitions) and ancestry (definition, distribution of participants). There was also insufficient detail and absent reporting for items needed to reproduce or critically assess the analytic validity of a PRS, including statistical validation model, risk score calibration, and data transparency and availability. We observed variable, often absent, discussion about the intended clinical purpose or utility of the score, and on how the PRS compared to standard of care. Papers also varied in their discussion of study limitations, particularly with regard to how the ancestry of the training and validation sets affected PRS generalizability.



# 221 Discussion

222 Polygenic risk scores have transformed human genetic research and emerged as potentially powerful tools 223 for the translation of genomic discoveries into clinical and public health benefits. However, standardized 224 and robust methods and reporting criteria are urgently needed in this area order to realize its potential. The 225 heterogeneity in the reporting of PRS to date-including what to report and how to report it-highlights the 226 challenges for accurate interpretation and confidence in PRS, especially with respect to assessing clinical 227 readiness. (Box 3) Critical aspects of PRS studies, including ancestry, predictive ability, and 228 transparency/availability of information needed to reproduce PRS, are frequently inadequately reported. 229 Without these aspects, PRS cannot be rigorously assessed and compared, even within the same disease 230 or recruitment cohorts. This underscores the need for a reporting standard with clear, specific definitions 231 that conveys the meaningful aspects of PRS development and testing, which are critical to understanding 232 PRS predictive ability and specificity for the intended target population and phenotype of interest.

233

234 The ClinGen Complex Disease Working Group utilized an iterative review process incorporating previous 235 standards, expert opinion and practical considerations to create an updated PRS-RS of 33 items, spanning 236 PRS derivation, testing and validation steps (Table 1). The reporting guideline is complemented by the 237 PGS Catalog (www.PGSCatalog.org), an online database that freely provides the underlying information 238 necessary to calculate the polygenic score (e.g., variants and weights) and curates important meta-data on 239 polygenic scores in structured, standardized formats. The PGS Catalog provides an open platform for 240 implementing reporting standards and lays the foundation for assessing best practices in polygenic score 241 research.

242

ClinGen has incorporated multiple sources to create a guide that is flexible, pragmatic, and informed. Researchers using this guideline may identify fringe cases that are inadequately covered, and the guide may become dated as PRS research continues to mature. However, by updating previous standards, involving current leaders in the field, and adapting the framework pragmatically to the barriers observed in recent literature, we aimed to provide a comprehensive perspective on the topic. In comparison to the original GRIPS statement, PRS-RS has expanded on elements related to understanding the clinical validity

of PRS and consequent risk models. Items such as risk score predicted clinical end outcome (introduction) and risk score intended purpose (discussion) bookend our guideline with the intended clinical framing of PRS reporting. Most other items in PRS-RS are consistent with the original GRIPS items but are presented in greater detail for more accurately assessing the clinical validity of PRS when needed. For example, the GRIPS item called "study design and setting" has been split into "study design" and "study recruitment," in acknowledgment of the importance of both distinct pieces of information in understanding study biases or limitations.

256

257 While the scope of our work encompasses clinical validity, it does not address the additional requirements 258 needed for clinical or public health utility, such as randomized trials with clinically meaningful outcomes, 259 health economic evaluations, or feasibility studies. In addition, the translation of structured data elements 260 into useful clinical parameters may not be direct. Two relevant examples are (i) the disease case definitions 261 utilized in training or validation in any particular PRS study may deviate (sometimes substantially) from 262 those utilized in any specific health system, and (ii) the definitions used for race/ancestry as outlined in the 263 PGS and GWAS Catalog<sup>1</sup> may also deviate from structured terms used to document ancestry information 264 in clinical care. Such translation issues potentially limit generalizability to target populations and warrant 265 further discussion. Nevertheless, we have emphasized the need for authors to be mindful of their intended 266 purpose and target audience when discussing their findings. Additionally, while the principles of this work 267 are clear, its scope does not include the complex commercial restrictions, such as intellectual property, that 268 may be placed on published studies regarding the reporting or distribution of polygenic scores, or the 269 underlying data thereof. This work can inform downstream regulation and transparency standards for PRS 270 as a commercial clinical tool.

271

The coordinated efforts of the ClinGen Complex Disease Working Group and PGS Catalog provide a set of compatible resources for researchers to deposit PRS information. The PGS Catalog provides an informatics platform with data integration and harmonization to other PGS as well as the source GWAS study through its sister platform, the GWAS Catalog.<sup>37</sup> In addition, it provides a structured database of scores (variants and effect sizes) and metadata requested in PRS-RS. With these tools, PRS-RS can be

277 mandated by leading peer-reviewed journals and, consequently, the quality and rigor of PRS research will
278 be elevated to a level which facilitates clinical implementation.

279

280 While we have provided explicit recommendations on how to acknowledge study design limitations and 281 their impact on the interpretation and generalizability of a PRS, future research should attempt to establish 282 best practices to guide the field. In addition, future reporting guidelines should address important guestions 283 about clinical readiness, specifically about intended use and target populations to help ease translation into 284 practice. While the working group has begun to address how changes in PRS practices should be 285 accounted for when reporting a PRS, future research should attempt to create a reporting guideline that 286 anticipates the consequences of new methods, such as deep learning. We encourage readers to visit the 287 ClinGen complex disease website (https://clinicalgenome.org/working-groups/complex-disease/) for any 288 future changes or amendments to the reporting guideline.

# 289 Methods

#### 290 ClinGen Complex Disease Working Group

291 The working group, founded by ClinGen in November 2018, comprised more than thirty experts with 292 epidemiological, statistical, disease-domain specific, implementation science, actionability, and ELSI 293 interests in polygenic risk score application. Members met twice a month to discuss current research, best 294 practices, and limitations within their respective areas of expertise. As a result of these meetings, the 295 workgroup decided to update previous genetic risk-score reporting standards<sup>17</sup> to current PRS practices. 296 This aim was finalized at the NHGRI Genomic Medicine XII: Genomics and Risk Prediction meeting in May 297 2019 with input from the external scientific community in terms of mission, scope, and long-term objectives 298 of the working group. Current descriptions of workgroup members and goals are available at: 299 https://clinicalgenome.org/working-groups/complex-disease/

300

#### 301 The Polygenic Score (PGS) Catalog

The PGS Catalog was founded in 2019 by researchers at the University of Cambridge UK, European Bioinformatics Institute (EMBL-EBI) and Baker Institute, and developed as a sister resource to the NHGRI-

304 EBI GWAS Catalog<sup>37</sup>. Its goal is to provide an open database of PGS and relevant metadata, so that 305 published PRS/PGS can be distributed, applied, and evaluated in a rigorous and replicable manner in both 306 research and clinical settings. It reports key information about how a PGS has been developed (e.g., variant 307 selection and computational methods), information about the specific datasets used for PGS development 308 and evaluation (e.g., sample size, ancestry, phenotype description), as well as the performance metrics 309 reported during PGS evaluation (e.g., effect sizes, covariates, and/or classification metrics). These data 310 are represented in a schema that links the Scores, Samples, and Performance Metrics presented in each 311 PGS publication. The PGS Catalog is available at www.PGSCatalog.org; additional descriptions of the 312 project, development, methods, full descriptions of the representation schema, along with links for PGS 313 submission can be found in the documentation (www.pgscatalog.org/about/) and will be described in a 314 future publication. (Lambert et al., in preparation)

315

#### 316 PRS Reporting Framework: Expert Guidelines Approach

PRS-RS was developed in iterative phases utilizing previous standards, expert opinion, and a pragmatic literature review process. First, the entire expert working group created the initial framework draft by adapting previous genetic risk-score reporting standards to current PRS methodologies. This was followed by a second round of revisions using a literature review. These steps led to a series of proposed revisions that were finalized with the entire working group. Finally, PRS-RS and PGS Catalog fields were mapped onto one another, and definitions were modified to reflect shared language, when possible.

323

#### 324 Draft guidelines from previous guidelines

The draft PRS-RS largely expanded on the GRIPS guidelines for genetic risk-prediction studies published in 2011.<sup>17</sup> To create the preliminary framework, we relied on expert opinion, and were guided by the PICOT framework used to compare heterogeneous clinical trial outcomes.<sup>13</sup> Our revisions focused on eliciting the individual components from previous standards that experts deemed independently important for transparent interpretation and reproducibility of a risk score (Supplemental Figure 1). We expanded the original GRIPS checklist of 25 items to 44 unique items, of which 33 items were needed for both training and validation cohorts. The majority of these additions were added to explicitly list discrete elements within

an individual GRIPS checklist item if those elements were determined by the work group to have significant impact in the interpretation of a PRS in terms of either analytic validity, clinical validity, or clinical utility. The PICOT framework did not add items to the reporting guidelines, but we did confirm that PICOT concepts were represented in the reporting guideline to facilitate downstream applications of comparing heterogeneous outcomes.

337

#### 338 **PRS-RS revisions using literature review**

339 We used the PRS-RS checklist to curate original research articles on polygenic risk-score development or 340 validation as a measure of pragmatism and clarity. Thirty-five papers were initially collected via the snowball 341 sampling search based on their use of the term "polygenic risk score" and their research in human 342 populations in preparation for the NHGRI Genomic Medicine XII meeting. Five papers were excluded from 343 the review because they were not original articles, did not develop or validate a PRS, duplicated a previous 344 study, or did not use genetic loci to construct their risk scores. Included articles spanned a variety of disease 345 domains including Alzheimer's disease, asthma, breast cancer, cerebrovascular event, colon cancer, 346 coronary heart disease, depression, fracture risk, Parkinson's disease, prostate cancer, and schizophrenia. 347 In addition, articles were selected for variety in the risk score category (development vs. external validation; 348 diagnostic vs. prognostic). Article references are available in the supplement.

349

350 Two independent reviewers assessed each article using the draft PRS reporting framework. A 10-person 351 volunteer subgroup of the larger working group met bi-weekly to resolve inter-reviewer discrepancies. If the 352 subgroup was unable to reach a consensus, one of four expert reviewers from the working group was 353 assigned to resolve discrepancies in a third review. This pilot of the reporting guideline on published PRS 354 revealed pragmatic areas for revision. Similar items were combined if they did not individually contribute 355 meaningful concepts for PRS interpretation. Items were removed if they did not contribute to overall 356 interpretation of the risk-score performance or target application. Definitions were expanded and revised to 357 address inconsistencies in inter-reviewer interpretation due to heterogeneous and vague reporting in the 358 literature. Items were kept as discrete items if we observed substantially missing or insufficiently detailed 359 reports on these items in the literature for transparency. When applicable, updated methodology was also

included in definitions. Finally, supplemental considerations were created to address fringe cases
 (Supplementary Table 1). Proposed reporting guideline revisions were ratified in monthly calls with the
 entire workgroup. This final 33-item PRS-RS is presented in *Table 1*.

363

Papers were re-curated using the final reporting guideline. The majority of papers (25/30) were predicting risk of developing disease with a few characterizing prognostic outcomes. Nearly half of the papers (13/30) developed a novel risk score, while the other half either externally validated a previously published risk score (9/30) or both developed and externally validated the risk score (6/30). Two manuscripts modified a previously published score. The composition of the final published risk scores were limited to genetic variables for the majority of papers (25/30), with only five producing an integrated risk score.

370

#### 371 PRS-RS harmonization with PGS Catalog

Two curators mapped reporting fields from the PGS Catalog onto the final PRS-RS guidelines. When possible, similar terminology was adopted between the two resources. A subset of fields in the PGS Catalog differ from PRS-RS due to restrictions in preserving integrity of the data infrastructure. The analogous ClinGen reporting item is listed in the PGS Catalog as a footnote to aid researchers, and this field mapping is available in the supplement (Supplementary Table 2).

## 377 Acknowledgements

We would like to acknowledge the input of the ClinGen Complex Disease Working Group members, including Carlos D. Bustamante, Michelle Meyer, Frank Harrell, David Kent, Peter Visscher, Tim Assimes, Sharon Plon, and Jonathan Berg. We would also like to thank Diane Durham for her editorial support and Angela Paolucci for her administrative support in the preparation and submission of this manuscript.

382

ClinGen is primarily funded by the National Human Genome Research Institute (NHGRI), through the following three grants: U41HG006834, U41HG009649, U41HG009650. ClinGen also receives support for content curation from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through the following three grants: U24HD093483, U24HD093486, U24HD093487.

387 The content is solely the responsibility of the authors and does not necessarily represent the official views 388 of the National Institutes of Health. Additionally, the views expressed in this article are those of the author(s) 389 and not necessarily those of the NHS, the NIHR, or the Department of Health, Research reported in this 390 publication was supported by the National Human Genome Research Institute of the National Institutes of 391 Health under Award Number U41HG007823 (EBI-NHGRI GWAS Catalog, PGS Catalog). In addition, we 392 acknowledge funding from the European Molecular Biology Laboratory. Individuals were funded from the 393 following sources: MIM was a Wellcome Investigator and an NIHR Senior Investigator with funding from 394 NIDDK (U01-DK105535); Wellcome (090532, 098381, 106130, 203141, 212259). MI and SAL were 395 supported by core funding from: the UK Medical Research Council (MR/L003120/1), the British Heart 396 Foundation (RG/13/13/30194; RG/18/13/33946) and the National Institute for Health Research (Cambridge 397 Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). This work was 398 also supported by Health Data Research UK, which is funded by the UK Medical Research Council, 399 Engineering and Physical Sciences Research Council, Economic and Social Research Council, 400 Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health 401 and Social Care Directorates, Health and Social Care Research and Development Division (Welsh 402 Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.

## 403 Author Contributions

HW, CT, MAI, IJK, CS, RR, KV, KK, KABG, PK, and GLW conducted the literature review of reporting
practices. HW, SAL, CT, MIA, JWO, IJK, RR, DB, EV, MIM, ACA, DFE, RAH, AVK, NC, CK, KE, EMR,
MCR, KEO, MJK, ACJWJ, KABG, PK, JALM, MI, and GLW provided feedback on the reporting framework.
HW, SAL, CT, MAI, JWO, IJK, AVK, JND, HP, EMR, MR, ACJWJ, KABG, PK, JALM, MI, and GLW wrote
and edited the manuscript text and items.

## 409 **Competing Interests**

MIM is on the advisory panels Pfizer, Novo Nordisk, and Zoe Global; Honoraria: Merck, Pfizer, Novo
Nordisk, and Eli Lilly; Research funding: Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen,

- 412 Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier & Takeda. As of June 2019, he is an employee
- 413 of Genentech with stock and stock options in Roche. No other authors have competing interests to declare.

# 414 Bibliography

- 416 1. Morales, J. et al. A standardized framework for representation of ancestry data in genomics studies,
- 417 with application to the NHGRI-EBI GWAS Catalog. *Genome Biol.* **19**, 21 (2018).
- 418 2. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies
  419 (GWAS Catalog). *Nucleic Acids Res.* 45, D896–D901 (2017).
- 420 3. Claussnitzer, M. et al. A brief history of human disease genetics. Nature (2020).
- 421 4. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. *Am. J. Hum.*422 *Genet.* 90, 7–24 (2012).
- 423 5. Pasaniuc, B. & Price, A. L. Dissecting the genetics of complex traits using summary association
  424 statistics. *Nat. Rev. Genet.* 18, 117–127 (2017).
- 425 6. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores.
  426 *Nat. Rev. Genet.* 19, 581–590 (2018).
- 427 7. Lambert, S. A., Abraham, G. & Inouye, M. Towards clinical utility of polygenic risk scores. *Hum. Mol.*428 *Genet.* 28, R133–R142 (2019).
- 429 8. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat.*430 *Genet.* 51, 584–591 (2019).
- 431 9. Chatterjee, N., Shi, J. & García-Closas, M. Developing and evaluating polygenic risk prediction models
  432 for stratified disease prevention. *Nat. Rev. Genet.* **17**, 392–406 (2016).
- 433 10. Huo, D. *et al.* Comparison of breast cancer molecular features and survival by african and european
  434 ancestry in the cancer genome atlas. *JAMA Oncol.* 3, 1654–1662 (2017).
- 435 11. Choi, J. *et al.* The associations between immunity-related genes and breast cancer prognosis in
  436 Korean women. *PLoS One* **9**, e103593 (2014).
- 437 12. Marston, N. A. *et al.* Predicting benefit from evolocumab therapy in patients with atherosclerotic
  438 disease using a genetic risk score: results from the FOURIER trial. *Circulation* 141, 616–623 (2020).

- Rios, L. P., Ye, C. & Thabane, L. Association between framing of the research question using the
  PICOT format and reporting quality of randomized controlled trials. *BMC Med. Res. Methodol.* 10, 11
  (2010).
- 442 14. Moons, K. G. M. *et al.* Transparent Reporting of a multivariable prediction model for Individual
  443 Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann. Intern. Med.* 162, W1-73 (2015).
- 15. von Elm, E. *et al.* Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
- statement: guidelines for reporting observational studies. *BMJ* **335**, 806–808 (2007).
- Little, J. *et al.* STrengthening the REporting of Genetic Association Studies (STREGA): an extension
  of the STROBE statement. *PLoS Med.* 6, e22 (2009).
- 448 17. Janssens, A. C. J. W. *et al.* Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS
  449 Statement. *PLoS Med.* 8, e1000420 (2011).
- 450 18. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores via penalized
  451 regression on summary statistics. *Genet. Epidemiol.* 41, 469–480 (2017).
- 452 19. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale data.
  453 *Gigascience* 8, (2019).
- Vilhjálmsson, B. J. *et al.* Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
- 456 21. Wilkinson, M. D. *et al.* The FAIR Guiding Principles for scientific data management and stewardship.
  457 *Sci. Data* 3, 160018 (2016).
- 458 22. Zhang, X. *et al.* Addition of a polygenic risk score, mammographic density, and endogenous hormones

to existing breast cancer risk prediction models: A nested case-control study. *PLoS Med.* 15,
e1002644 (2018).

- 461 23. Kuchenbaecker, K. B. *et al.* Evaluation of polygenic risk scores for breast and ovarian cancer risk 462 prediction in BRCA1 and BRCA2 mutation carriers. *J. Natl. Cancer Inst.* **109**, (2017).
- 463 24. Mavaddat, N. *et al.* Polygenic risk scores for prediction of breast cancer and breast cancer subtypes.
  464 *Am. J. Hum. Genet.* **104**, 21–34 (2019).
- 25. Nikpay, M. *et al.* A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of
  coronary artery disease. *Nat. Genet.* 47, 1121–1130 (2015).

- 467 26. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk
- 468 equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
- 469 27. FinnGen et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of
- 470 cardiometabolic diseases and common cancers. Nat. Med. (2020). doi:10.1038/s41591-020-0800-0
- 471 28. Elliott, J. *et al.* Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical
- 472 Risk Score for Coronary Artery Disease. JAMA 323, 636–645 (2020).
- 473 29. Inouye, M. *et al.* Genomic risk prediction of coronary artery disease in 480,000 adults: implications for
  474 primary prevention. *J. Am. Coll. Cardiol.* **72**, 1883–1893 (2018).
- 475 30. Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016).
- 476 31. Ganna, A. *et al.* Multilocus genetic risk scores for coronary heart disease prediction. *Arterioscler.*477 *Thromb. Vasc. Biol.* 33, 2267–2272 (2013).
- 478 32. Kullo, I. J. et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect
- 479 on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). *Circulation* **133**, 1181–
  480 1188 (2016).
- 481 33. U.S. National Library of Medicine. Home ClinicalTrials.gov. at <https://clinicaltrials.gov/>
- 482 34. Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for complex traits.
  483 *Nature* 570, 514–518 (2019).
- 484 35. Choi, S. W., Mak, T. S. H. & O'Reilly, P. A guide to performing Polygenic Risk Score analyses. *BioRxiv*485 (2018). doi:10.1101/416545
- 486 36. Yadlowsky, S. *et al.* Clinical implications of revised pooled cohort equations for estimating
  487 atherosclerotic cardiovascular disease risk. *Ann. Intern. Med.* **169**, 20–29 (2018).
- 488 37. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies,
- 489 targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).

# 491 Table 1. ClinGen PRS Reporting Guideline.

492 Bold= training and validation, when applicable

Introduction				
Article Type	Specify whether authors are developing a risk score and/or externally validating a previously published PRS. When externally validating or combining previously published PRS, include identifier(s) of original PRS (PMID, PGS catalog ID).			
Risk Score Category	Specify the risk score's purpose as risk prediction, diagnostic, prognostic, or therapeutic (or combination of these).			
Risk Score Predicted Clinical End Outcome	When describing the risk score purpose, include the clinical end outcome predicted by the final PRS model. If the predicted outcome is a clinical feature or endpoint within a specific disease, state the disease. Inclusion/exclusion criteria are specified in the methods.			
	Methods: Study Design			
Study Design	Include study design details including study type (e.g., cohort, case control, cross sectional), and whether the predicted clinical end outcome is defined by incidence or prevalence. State whether the data are primary or secondary data. If secondary analysis, include a reference to the original study. For PRS that combine samples from multiple studies, include this information for each study.			
Study Recruitment	Stated or reference (if secondary analysis) recruitment details, such as method and years.			
Phenotype of Interest	Provide the inclusion and exclusion criteria used to define the predicted clinical end outcome stated in the introduction. If the predicted outcome is a clinical feature or endpoint within a specific disease, provide the inclusion and exclusion criteria used to define that disease. Include details on how inclusion and exclusion information was ascertained (e.g., ICD codes, e-phenotyping algorithms, chart review, self-report). Authors should explicitly state the number of cases and controls included.			
	For dichotomous data, also include inclusion and exclusion criteria for defining the cases and controls. Transformation of continuous data into binary outcomes should be detailed for reproducibility. Authors should explicitly state the number of controls included.			
Methods: Variable Definitions				
Ancestry	Include the distribution of ancestral background for all samples used to generate or evaluate a PRS, and the data source of this ancestry information (e.g., self-report, genotyping). Ancestry information should be reported using the <u>standardized framework</u> developed by the NHGRI-EBI GWAS Catalog and ideally include detailed information beyond this when available. When combining samples from multiple studies, aggregate ancestral distribution information is sufficient. If genetic ancestry was considered, estimation methods should be detailed as well as discussing how this was utilized in analysis.			

	Geographic location should not be used as a proxy to infer ancestry information.	
Age	Include the age distribution of the total data set used to generate a single PRS (whether a single sample set, or the summary of combined samples) using the mean, standard deviation and range. Provide the age distribution by case/control status, if applicable.	
Sex	Include the sex distribution of the total data set used to generate a single PRS (whether a single sample set, or the summary of combined samples) using the counts and percentages of total sample. State if sex was inferred from self-report or genetic information. Provide the sex distribution by case/control status, if applicable.	
Risk Model Genetic Data Acquisition	Provide method for acquiring genetic information (sequencing vs. genotyping) in the PRS sample, including information about genome build and technical details of the assay. If imputing, specify the populations on the imputation panel, and provide the imputation quality for SNPs included in PRS. Report any imputation quality filters to exclude low quality imputation SNPs.	
Risk Model Parameter Specifications	Explicitly state all terms used in the final risk model, including SNPs and any non-genetic variables. Authors should detail inclusion/exclusion criteria for all SNPs and other variables in the final model.	
	Statistical procedures for selecting SNPs from a GWAS for inclusion in the final PRS model are provided in the "Statistical Model Fitting Procedure." Provide a reference for discovery GWAS and whether any adjustments were performed in the GWAS.	
	If parameters were selected from another study, include reference (PMID, PGS catalog ID).	
Clinical variable definition(s)	For any non-genetic variables included in the risk model, provide inclusion and exclusion criteria to define each variable, along with data source for that information (e.g., ICD codes, e-phenotyping algorithms, chart review, self-report). Indicate whether the variable is dichotomous or continuous.	
Missing Data	Authors should explicitly state how missing data were handled for all variables included in the model, genetic and non-genetic.	
Sub-Analyses	For any sub-analyses performed, provide inclusion and exclusion criteria used to stratify or subset the sample, any cut-offs used with justification provided, and the data source for this information (e.g., ICD codes, e-phenotyping algorithms, chart review, self-report). Explicitly state the number of cases included in the sub-analyses.	
Methods: Analysis		
Polygenic Risk Score Estimation	Describe the statistical methods used to calculate risk score, primarily how the genetic data are transformed into a single score from individual risk variants. This includes information on how variants were weighted, and how the weights were derived.	
Statistical Model Fitting Procedure	State the fitting procedure utilized to select the final version of the model. Details should include criteria for inclusion of SNPs (such as effect size or P-value threshold), if model was selected for optimal performance, and if so, the measures used to assess performance.	

Risk Model Type	Detail statistical methods used to estimate risk, either relative or absolute, from the continuous risk score distribution. Authors should detail if risk is cumulative or cross-sectional, as well as the appropriate comparison groups if relative risk presented.		
	Report time <i>until</i> predicted risk (eg. 5-year, 10-year, lifetime). In a relative hazard model, the study period or follow up time may be used. In an absolute risk model, state the time until predicted event. Authors should be careful not to simply report total length of study.		
Risk Score Calibration	Describe measures used to assess calibration of the risk score and whether any variables were included beyond the risk score in this analysis.		
Risk Score Discrimination	Describe measures used to assess discrimination of the risk score and whether any variables were included beyond the risk score in this analysis.		
Statistical Validation Model	Outline procedures utilized to validate the risk score, including whether validation was performed, and the specific statistical model used during validation, especially if different than those used in the training set. Other details should include whether validation was internal or with an external validation set. Authors should include how missing data were handled.		
Statistical Subgroup Analyses	For any sub-analyses performed, include details about statistical procedures specific to that subgroup that differ from the main analysis.		
Results			
Risk Score Distribution	Include a general description of the distribution of the risk score, as well as model fit measures. This details the continuous distribution output directly from the risk model.		
Risk Score Predictive Ability	State if risk model output is in terms of absolute or relative risk. If relative risk, include information about the reference population in respect to all relevant variables. It should be explicitly stated if the risk measure has been adjusted for other variables as previously defined in methods.		
	If relative risk, include information about the reference population and risk score distribution in the general population. For absolute risk, include the prevalence/incidence of the predicted outcome in the general population.		
	Enough detail should be included to enable readers to compute measures of risk score predictive ability such as AUC, sensitivity, specificity, PPV, NPV.		
Risk Score Discrimination	Include metrics assessing discrimination of the risk score and whether other variables are included beyond the risk score in this analysis.		
Risk Score Calibration	Include metrics assessing calibration of the risk score and whether other variables are included beyond the risk score in this analysis.		

Subgroup Analyses	For any subgroup analyses, report all measures (predictive ability, distribution, discrimination, calibration).			
	Discussion			
Risk Model Interpretation	Summarize the risk score in terms of what it predicts, how well, and in whom. The predicted outcome predicted should be consistent with the introduction. Explicitly mention the performance of the risk model beyond non-genetic risk factors if non-genetic factors were included in the model. Target population should reflect the sample used in risk model development and validation (eg. ancestry, age, sex, other characteristics).			
Limitations	Outline limitations in interpreting results. This includes, but is not limited to, study design restrictions, ascertainment biases, the distribution participant-level traits (ancestry, age, comorbidities), accuracy/specificity of phenotype data, and any statistical considerations. In addition, make note of any unknown reporting items from previous sections. Authors should consider and discuss the impact of these limitations on the interpretation of the risk score and any downstream replication needed.			
Generalizability	Discuss which populations this score may be applied to and explicitly address any issues with generalizability beyond the included populations. Discuss whether the risk score has been externally validated, or if the sample is limited with respect to ancestry, age, or other variables.			
Risk Score Intended Purpose	Discuss whether there is an intended clinical purpose or utility to the score. If so, discuss the "clinic readiness" and next steps with respect to the interpretation, limitations, and generalizability of the model. Discuss how the predictive ability of the model is benchmarked against current standard of care or other published work (such as existing PRS) on predicting the outcome of interest. If not, discuss why the PRS should not be used for clinical purposes.			
Data Transparency and Availability	Information sufficient to calculate the PRS and/or risk model on external samples should be made available. For genetic variables this would include information about the variants (e.g., rsID, chromosomal location, effect allele, and the effect weight) that comprise the score; PRS with this information can be published in the PGS Catalog for findability and to promote re-use and comparison with other established scores. Weights for non-genetic variables should also be provided to make the risk model calculable in the same way.			